Recent News

• 03.03.2025 - Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
• 02.20.2025 - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science that Supports Development of its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
• 02.04.2025 - Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 11.18.2024 - Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
• 10.22.2024 - Cardiol Therapeutics to Advance CardiolRx™ into a Late-stage Trial in Patients with Recurrent Pericarditis
• 10.11.2024 - Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
• 10.10.2024 - Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
• 10.10.2024 - Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Recent Filings

• 03.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.03.2025 - EX-99.1 EX-99.1
• 02.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.20.2025 - EX-99.1 EX-99.1
• 02.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.04.2025 - EX-99.1 EX-99.1
• 11.18.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.14.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.06.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.22.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]